Click on highlighted names for speaker presentations.

Presentations are in Adobe Acrobat (PDF) format.

Did you like this conference? Tell us why juliab@healthtech.com

Corporate Sponsors

Corporate Support 

Monday, June 16

7:30-8:30am Continental Breakfast

8:30-8:40 Chairperson's Remarks
Dr. Mark Nuttal, Section Leader, GlaxoSmithKline

8:40-9:10 RNAi-Based Validation Platform for Rapid Functional Characterization of Brain Disease-Related Genes
Dr. Li Gan, Senior Scientist, Department of Molecular Biology & Protein Chemistry, AGY Therapeutics

9:10-9:40 Tools for Expediting Target Validation
Dr. Mark Nuttal

9:40-10:10 Knockdown in Target Validation
Dr. Kathrin Heermeier, Senior Scientist, Aventis Pharma

10:10-10:30 Coffee Break with Poster Viewing

10:30-11:00 Development of a Robust Screen for Active siRNA Duplexes and Using siRNA Technology for Target Validation
Mr. Xu Ren, Research Scientist, Amgen Corp.

11:00-11:30 Arrayed Adenoviral Knockdown Vectors for Target Discovery and Validation
Dr. Helmuth van Es, Director of Molecular and Cellular Biology, Galapagos Genomics; and Dr. Michael Briggs, Director of Genomics, Pharmacia Corporation

11:30-12:00 Genomewide Knockdown Strategies: RNAi Applications
Dr. Thierry Bogaert, Chief Executive Officer, Devgen nv

12:00-1:30 Technology Workshop (seating is limited) or lunch on your own

Sponsored by IBM

1:30-1:40 Chair's Remarks
Dr. Hans-Peter Vornlocher, Head of Research and Development, Ribopharma AG

1:40-2:10 Control of Gene Expression by MicroRNAs
Dr. Frank Slack, Assistant Professor, Department of Molecular, Cellular and Developmental Biology, Yale University

2:10-2:40 Reliable, High-Throughput siRNA Synthesis and RNAi Applications
Dr. William S. Marshall, Executive Vice President of Research & Development, Dharmacon Research, Inc.

2:40-3:10 RNAi in Drug Development
Dr. Dimitri Samarsky, Technology Development Manager, Sequitur, Inc.

3:10-3:30 Refreshment Break with Poster Viewing

3:30-4:00 Homologous Gene Silencing in Transgenic Mammals: Exploiting Opportunities for in Vivo Target Validation and Functional Genomics
Dr. Ken C. Reed, Director, Research and Technology, Benitec, Australia Ltd.

4:00-4:30 Using siRNA to Diminish Expression of Exogenous and Endogenous Genes in Vivo and in Vitro
Dr. Beverly L. Davidson, Roy J. Carver Professor in Internal Medicine and Professor in Neurology and Physiology & Biophysics, University of Iowa College of Medicine

4:30-5:00 Effective Nonviral Delivery of siRNA and siRNA-Expressing Vectors into Cells in Vitro and in Vivo
Dr. James E. Hagstrom, Vice President, Scientific Operations, Mirus Corp.

7:30-8:15am Continental Breakfast/Technology Workshop: CHI's Drug Discovery and Development Map for the Post Genome Era
Presented by Phillips Kuhl, President, Cambridge Healthtech Institute

8:30-8:40 Chairperson's Remarks
Dr. Reuven Agami, Group Leader, Division of Tumor Biology, The Netherlands Cancer Institute

8:40-9:10 RNA Interference Tools for Cancer Applications
Dr. Reuven Agami

9:10-9:40 RNAi Technology in Oncology Target Discovery and Validation
Dr. Brent A. Rupnow, Senior Research Investigator, Bristol-Myers Squibb Pharmaceutical Research Institute

9:40-10:10 RNA-Interference as a Platform for Development of Cancer Therapeutics
Dr. Hans-Peter Vornlocher

10:10-10:30 Coffee Break with Poster Viewing

10:30-11:00 Using RNAi Selectively to Investigate Mechanisms of Hormone-Regulated Growth of Breast Cancer Cells
Dr. Stephen Safe, Sid Kyle Professor of Toxicology, Department of Veterinary Physiology & Pharmacology, Texas A&M University

11:00-11:30 RNAi and Viral-Induced Cancer
Dr. Jo Milner, Professor of Cell Biology, Yorkshire Cancer Research Laboratory, University of York

11:30-12:00 Panel Discussion

12:00-1:30 Luncheon Technology Workshop:
Annotation of the Human Genome by High-Throughput Sequence Analysis of Naturally Occurring Proteins
Presented by Jonathan Sheldon, Confirmant Ltd.
Sponsored by Confirmant

1:30-1:40 Chairperson's Remarks
Dr. John Rossi, Associate Director for Laboratory Research, City of Hope Comprehensive Cancer Center, City of Hope

1:40-2:10 Using Expressed Long Inhibitory dsRNA or eliRNA as a Therapeutic for Treatment of Viral Infections
Dr. C. Satishchandran, Chief Science Officer, Nucleonics, Inc.

2:10-2:40 Expression of siRNA Targeted against HIV-1 rev Transcripts in Human Cells
Dr. John Rossi

2:40-3:10 Using siRNA to Inhibit Early and Late Steps of Human Immunodeficiency Virus Replication in Human Cell Lines and Primary Lymphocytes by Targeting siRNAs to Various Regions of the HIV-1 Genome
Dr. Mario Stevenson, Professor of Molecular Medicine, University of Massachusetts Medical School

3:10-3:40 RNAi-Mediated Inhibition of HIV Replication in Primary Macrophages
Dr. Premlata Shankar, Junior Investigator and Assistant Professor of Pediatrics, The Center for Blood Research, Harvard Medical School

3:40-4:00 Refreshment Break with Poster Viewing

4:00-4:10 Keynote Introduction

4:10-4:50 Plenary Keynote: The Alpha Project and the Dream of a Predictive Biology
Dr. Roger Brent, President and Research Director, The Molecular Sciences Institute; and Adjunct Professor, University of California, San Francisco

4:50-6:30 Opening Reception in the Exhibit Hall

Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls, Ma 02464
Phone: 617-630-1300
Fax:  617-630-1325
Email: chi@healthtech.com